Kinetic profiles and management of hepatitis B virus reactivation in patients with immune-mediated inflammatory diseases

Arthritis Care and Research

Volumn 65, Issue 9, 2013, Pages 1504-1514

  Droz, Nina ^a   Gilardin, Laurent ^b   Cacoub, Patrice ^c   Berenbaum, Francis ^b   Wendling, Daniel ^d   Godeau, Bertrand ^e   Piette, Anne Marie ^f   Dernis, Emmanuelle ^g   Ebbo, Mikael ^h   Fautrel, Bruno ^c   Le Guenno, Guillaume ⁱ   Mekinian, Arsène ^j   Bernard Chabert, Brigitte ^k   Costedoat Chalumeau, Nathalie ^c   Descloux, Elodie ^l   Michot, Jean Marie ^m   Radenne, Sylvie ⁿ   Rigolet, Aude ^c   Rivière, Sophie ^o   Yvin, Jean Luc ^g   Thibault, Vincent ^c   Thabut, Dominique ^c   Pol, Stanislas ^a   Guillevin, Loïc ^a   Mouthon, Luc ^a   Terrier, Benjamin ^a   more..

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b HÔPITAL SAINT ANTOINE   (France)

^c SORBONNE UNIVERSITÉ   (France)

^d UNIVERSITY HOSPITAL OF BESANÇON   (France)

^e HENRI MONDOR HOSPITAL   (France)

^f FOCH HOSPITAL   (France)

^g Centre Hospitalier Universitaire   (France)

^h HÔPITAL DE LA CONCEPTION   (France)

ⁱ UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

^j HÔPITAL JEAN VERDIER   (France)

^k REIMS UNIVERSITY HOSPITAL   (France)

^l Centre Hospitalier Territorial   (New Caledonia)

^m UNIVERSITÉ PARIS SACLAY   (France)

ⁿ HOSPICES CIVILS DE LYON   (France)

^o MONTPELLIER UNIVERSITY HOSPITAL   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; AZATHIOPRINE; CERTOLIZUMAB PEGOL; CORTICOSTEROID; CYCLOPHOSPHAMIDE; ENTECAVIR; ETANERCEPT; GOLIMUMAB; HEPATITIS B SURFACE ANTIGEN; HYDROXYCHLOROQUINE; INFLIXIMAB; LAMIVUDINE; LEFLUNOMIDE; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; SALAZOSULFAPYRIDINE; STEROID; TENOFOVIR; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; VIRUS DNA;

ADULT; ALGORITHM; ANTIVIRAL THERAPY; ARTICLE; CLINICAL ARTICLE; CONNECTIVE TISSUE DISEASE; DISEASE SEVERITY; FEMALE; HEPATITIS; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNE MEDIATED INJURY; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATORY DISEASE; KINETICS; MALE; OUTCOME ASSESSMENT; RHEUMATOID ARTHRITIS; VASCULITIS; VIRUS REACTIVATION;

ADULT; AGED; DISEASE MANAGEMENT; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; IMMUNE SYSTEM DISEASES; IMMUNOSUPPRESSION; INFLAMMATION; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; VIRUS ACTIVATION;

EID: 84883383172     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.21990     Document Type: Article

References (50)

1. Lee WM,. Hepatitis B virus infection. N Engl J Med 1997; 337: 1733-45.
2. Lai CL, Ratziu V, Yuen MF, Poynard T,. Viral hepatitis B. Lancet 2003; 362: 2089-94.
3. Institut de Veille Sanitaire. Prévalence des hépatites B et C en France en 2004. 2007. URL: http://www.invs.sante.fr/publications/2006/ prevalence-b-c/vhb-france-2004.pdf.
4. Werle-Lapostolle B, Bowden S, Locarnini S, Wursthorn K, Petersen J, Lau G, et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 2004; 126: 1750-8.
5. Hoofnagle JH,. Reactivation of hepatitis B. Hepatology 2009; 49: S156-65.
6. Hui CK, Bowden S, Jackson K, Au WY, Fong DY, Lie AK, et al. Clinical significance of intrahepatic hepatitis B virus covalently closed circular DNA in chronic hepatitis B patients who received cytotoxic chemotherapy [letter]. Blood 2005; 105: 2616-7.
7. Lok AS, McMahon BJ,. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661-2.
8. Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008; 59: 762-84.
9. Jansen TL, Mulder CJ,. Rheumatology meets hepatology in 2012: a clinician's guideline for TNF inhibitors in hepatitis B/C virus carriers. Expert Opin Biol Ther 2012; 12: 391-3.
10. Kuwabara H, Fukuda A, Tsuda Y, Shibayama Y,. Precore mutant hepatitis B virus-associated fulminant hepatitis during infliximab therapy for rheumatoid arthritis. Clin Rheumatol 2013; 32 Suppl: S47-9.
11. Chung SJ, Kim JK, Park MC, Park YB, Lee SK,. Reactivation of hepatitis B viral infection in inactive HBsAg carriers following anti-tumor necrosis factor-α therapy. J Rheumatol 2009; 36: 2416-20.
12. Colbert C, Chavarria A, Berkelhammer C,. Fulminant hepatic failure in chronic hepatitis B on withdrawal of corticosteroids, azathioprine and infliximab for Crohn's disease [letter]. Inflamm Bowel Dis 2007; 13: 1453-4.
13. Esteve M, Saro C, Gonzalez-Huix F, Suarez F, Forne M, Viver JM,. Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis. Gut 2004; 53: 1363-5.
14. Garcia-Vidal C, Rodriguez-Fernandez S, Teijon S, Esteve M, Rodriguez-Carballeira M, Lacasa JM, et al. Risk factors for opportunistic infections in infliximab-treated patients: the importance of screening in prevention. Eur J Clin Microbiol Infect Dis 2009; 28: 331-7.
15. Li S, Kaur PP, Chan V, Berney S,. Use of tumor necrosis factor-α (TNF-α) antagonists infliximab, etanercept, and adalimumab in patients with concurrent rheumatoid arthritis and hepatitis B or hepatitis C: a retrospective record review of 11 patients. Clin Rheumatol 2009; 28: 787-91.
16. Loras C, Gisbert JP, Minguez M, Merino O, Bujanda L, Saro C, et al. Liver dysfunction related to hepatitis B and C in patients with inflammatory bowel disease treated with immunosuppressive therapy. Gut 2010; 59: 1340-6.
17. Ojiro K, Naganuma M, Ebinuma H, Kunimoto H, Tada S, Ogata H, et al. Reactivation of hepatitis B in a patient with Crohn's disease treated using infliximab. J Gastroenterol 2008; 43: 397-401.
18. Oniankitan O, Duvoux C, Challine D, Mallat A, Chevalier X, Pawlotsky JM, et al. Infliximab therapy for rheumatic diseases in patients with chronic hepatitis B or C. J Rheumatol 2004; 31: 107-9.
19. Ostuni P, Botsios C, Punzi L, Sfriso P, Todesco S,. Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate [letter]. Ann Rheum Dis 2003; 62: 686-7.
20. Robinson H, Walker-Bone K,. Anti-TNF-α therapy for rheumatoid arthritis among patients with chronic hepatitis B infection. Rheumatology (Oxford) 2009; 48: 448-50.
21. Roux CH, Brocq O, Breuil V, Albert C, Euller-Ziegler L,. Safety of anti-TNF-α therapy in rheumatoid arthritis and spondylarthropathies with concurrent B or C chronic hepatitis. Rheumatology (Oxford) 2006; 45: 1294-7.
22. Vassilopoulos D, Apostolopoulou A, Hadziyannis E, Papatheodoridis GV, Manolakopoulos S, Koskinas J, et al. Long-term safety of anti-TNF treatment in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection. Ann Rheum Dis 2010; 69: 1352-5.
23. Verhelst X, Orlent H, Colle I, Geerts A, De Vos M, Van Vlierberghe H,. Subfulminant hepatitis B during treatment with adalimumab in a patient with rheumatoid arthritis and chronic hepatitis B. Eur J Gastroenterol Hepatol 2010; 22: 494-9.
24. Yuen MF, Wong DK, Lee CK, Tanaka Y, Allain JP, Fung J, et al. Transmissibility of hepatitis B virus (HBV) infection through blood transfusion from blood donors with occult HBV infection. Clin Infect Dis 2011; 52: 624-32.
25. Perez-Alvarez R, Diaz-Lagares C, Garcia-Hernandez F, Lopez-Roses L, Brito-Zeron P, Perez-de-Lis M, et al. Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy: analysis of 257 cases. Medicine (Baltimore) 2011; 90: 359-71.
26. Matsumoto T, Marusawa H, Dogaki M, Suginoshita Y, Inokuma T,. Adalimumab-induced lethal hepatitis B virus reactivation in an HBsAg-negative patient with clinically resolved hepatitis B virus infection [letter]. Liver Int 2010; 30: 1241-2.
27. Urata Y, Uesato R, Tanaka D, Kowatari K, Nitobe T, Nakamura Y, et al. Prevalence of reactivation of hepatitis B virus replication in rheumatoid arthritis patients. Mod Rheumatol 2011; 21: 16-23.
28. Lan JL, Chen YM, Hsieh TY, Chen YH, Hsieh CW, Chen DY, et al. Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor α therapy. Ann Rheum Dis 2011; 70: 1719-25.
29. Germanidis G, Hytiroglou P, Zakalka M, Settas L,. Reactivation of occult hepatitis B virus infection, following treatment of refractory rheumatoid arthritis with abatacept [letter]. J Hepatol 2012; 56: 1420-1.
30. Rodriguez-Escalera C, Fernandez-Nebro A,. The use of rituximab to treat a patient with ankylosing spondylitis and hepatitis B [letter]. Rheumatology (Oxford) 2008; 47: 1732-3.
31. Ito S, Nakazono K, Murasawa A, Mita Y, Hata K, Saito N, et al. Development of fulminant hepatitis B (precore variant mutant type) after the discontinuation of low-dose methotrexate therapy in a rheumatoid arthritis patient. Arthritis Rheum 2001; 44: 339-42.
32. Tamori A, Koike T, Goto H, Wakitani S, Tada M, Morikawa H, et al. Prospective study of reactivation of hepatitis B virus in patients with rheumatoid arthritis who received immunosuppressive therapy: evaluation of both HBsAg-positive and HBsAg-negative cohorts. J Gastroenterol 2011; 46: 556-64.
33. Flowers MA, Heathcote J, Wanless IR, Sherman M, Reynolds WJ, Cameron RG, et al. Fulminant hepatitis as a consequence of reactivation of hepatitis B virus infection after discontinuation of low-dose methotrexate therapy. Ann Intern Med 1990; 112: 381-2.
34. Cobeta Garcia JC, Medrano M,. Reactivation of hepatitis B in a patient with spondyloarthritis after the suspension of methotrexate and efficacy of treatment with antivirals in association to adalimumab. Reumatol Clin 2011; 7: 200-2. In Spanish.
35. Mori S,. Past hepatitis B virus infection in rheumatoid arthritis patients receiving biological and/or nonbiological disease-modifying antirheumatic drugs. Mod Rheumatol 2011; 21: 621-7.
36. Pyrpasopoulou A, Douma S, Vassiliadis T, Chatzimichailidou S, Triantafyllou A, Aslanidis S,. Reactivation of chronic hepatitis B virus infection following rituximab administration for rheumatoid arthritis. Rheumatol Int 2011; 31: 403-4.
37. Cheng J, Li JB, Sun QL, Li X,. Reactivation of hepatitis B virus after steroid treatment in rheumatic diseases [letter]. J Rheumatol 2011; 38: 181-2.
38. Zeitz J, Mullhaupt B, Fruehauf H, Rogler G, Vavricka SR,. Hepatic failure due to hepatitis B reactivation in a patient with ulcerative colitis treated with prednisone [letter]. Hepatology 2009; 50: 653-4.
39. Nagashima T, Minota S,. Long-term tocilizumab therapy in a patient with rheumatoid arthritis and chronic hepatitis B. Rheumatology (Oxford) 2008; 47: 1838-40.
40. Yang CH, Wu TS, Chiu CT,. Chronic hepatitis B reactivation: a word of caution regarding the use of systemic glucocorticosteroid therapy. Br J Dermatol 2007; 157: 587-90.
41. Kuo SC, Lee HT, Chen WS, Chou CT, Tsai CY,. Deterioration of the liver biochemistry due to reactivation of chronic hepatitis B during etanercept treatment for rheumatoid arthritis. BMJ Case Rep 2009; 2009.
42. Kim PS, Ho GY, Prete PE, Furst DE,. Safety and efficacy of abatacept in eight rheumatoid arthritis patients with chronic hepatitis B. Arthritis Care Res (Hoboken) 2012; 64: 1265-8.
43. Tan J, Zhou J, Zhao P, Wei J,. Prospective study of HBV reactivation risk in rheumatoid arthritis patients who received conventional disease-modifying antirheumatic drugs. Clin Rheumatol 2012; 31: 1169-75.
44. Hagiyama H, Kubota T, Komano Y, Kurosaki M, Watanabe M, Miyasaka N,. Fulminant hepatitis in an asymptomatic chronic carrier of hepatitis B virus mutant after withdrawal of low-dose methotrexate therapy for rheumatoid arthritis [letter]. Clin Exp Rheumatol 2004; 22: 375-6.
45. Kato M, Atsumi T, Kurita T, Odani T, Fujieda Y, Otomo K, et al. Hepatitis B virus reactivation by immunosuppressive therapy in patients with autoimmune diseases: risk analysis in hepatitis B surface antigen-negative cases. J Rheumatol 2011; 38: 2209-14.
46. Gwak GY, Koh KC, Kim HY,. Fatal hepatic failure associated with hepatitis B virus reactivation in a hepatitis B surface antigen-negative patient with rheumatoid arthritis receiving low dose methotrexate. Clin Exp Rheumatol 2007; 25: 888-9.
47. Zingarelli S, Frassi M, Bazzani C, Scarsi M, Puoti M, Airo P,. Use of tumor necrosis factor-α-blocking agents in hepatitis B virus-positive patients: reports of 3 cases and review of the literature. J Rheumatol 2009; 36: 1188-94.
48. Terrier B, Pol S, Thibault V, Gottenberg JE, Cacoub P,. Management of the risk of hepatitis B virus reactivation in patients receiving immunosuppressive and immunomodulatory agents in internal medicine: data from the REACTI-B survey and proposal for a management algorithm. Rev Med Interne 2012; 33: 4-12. In French.
49. Lai CL, Yuen MF,. The natural history of chronic hepatitis B. J Viral Hepat 2007; 14 Suppl: 6-10.
50. Zoulim F,. Hepatitis B virus resistance to antiviral drugs: where are we going? Liver Int 2011; 31 Suppl: 111-6.